Vandetanib (ZD6474)

For research use only.

Catalog No.S1046

79 publications

Vandetanib (ZD6474) Chemical Structure

CAS No. 443913-73-3

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 117 In stock
USD 147 In stock
USD 257 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vandetanib (ZD6474) has been cited by 79 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Targets
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
40 nM 110 nM 500 nM
In vitro

Vandetanib also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6). [1] Vandetanib displays an inhibitory effect on the basal ABCG2-ATPase. Parental and ABCG2-expressing A431 cells showed similar sensitivities toward Vandetanib. Exposure to EGFR inhibitors decreases pEGFR levels in A431 cells, with Vandetanib displaying only a moderate effect. Vandetanib displays a slight but measurable effect, whereas gefitinib, pelitinib and neratinib completely inhibit ABCG2-mediated efflux of mitoxantrone from A431/ABCG2 cells, similarly to the specific ABCG2 inhibitor Ko143. [2] Vandetanib inhibits both PC3wt and PC3R cell lines with similar IC50 of 13.3 μM and 11.5 μM, respectively. [3] Vandetanib suppresses phosphorylation of VEGFR2 in HUVEC and EGFR in hepatoma cells and inhibits cell proliferation. [4] Vandetanib causes an accumulation of cells in the G0-G1 phases in GEO and OVCAR-3 cells and increases apoptosis in OVCAR-3, ZR-75-1, MCF-10A ras, and GEO cells. Vandetanib causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. Vandetanib treatment results in a dose-dependent inhibition of soft agar growth in seven human cell lines (breast, colon, gastric, and ovarian) with functional EGFR but lacking VEGFR2. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SN179  M4DpSWZ2dmO2aX;uJGF{e2G7 M1vleFUxOOLCiX7NxsA> MVSxOkBp NInBUZpqdmO{ZXHz[ZMhS1iFUkSg[ZhxemW|c3nvckB{cWewaX\pZ4FvfGy7 Mn7WNlU3PzZ4OUG=
SN186 MnPJSpVv[3Srb36gRZN{[Xl? MoHuOVAx6oDLbl5CpC=> NX\U[WVUOTZiaB?= MkTHbY5kemWjc3XzJGNZS1J2IHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? Mm\jNlU3PzZ4OUG=
SN179  M3;BXGZ2dmO2aX;uJGF{e2G7 M2L2eFUxOOLCiX7NxsA> NX;jSVk3OTZiaB?= NVyzeHJm\W6qYX7j[ZMhfGinIFPYR2wyOiCmaYLlZ5Rm\CCvaXfyZZRqd25? NFjCNIozPTZ5Nk[5NS=>
SN179  NY\xXZZITnWwY4Tpc44hSXO|YYm= NXztbYJSPTBy4pEJcm3DqA>? NH6ycooyPiCq NGTOdJBqdmO{ZXHz[ZMh[mG|YXygcYloemG2aX;uxsA> NWHvdnBUOjV4N{[2PVE>
Jurkat MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW3NuKhcMLi NX\jXnRQT0l3ME2xMlUhyrFiMD6yJO69VQ>? NHfTXZEzPDZ6MUKwOS=>
K-562 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T2OVczyqCqwrC= MlHOS2k2OD1zLkigxtEhOC5zIN88US=> Ml3NNlQ3QDF{MEW=
NCTC-2544 NWfVXGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInqXHY4OsLiaNMg M1TuUmdKPTB;ND62JOKyKDBwMzFOwG0> MVmyOFY5OTJyNR?=
A-431 M3K2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCyO|LDqGkEoB?= NIH6UWVIUTVyPUKuOEDDuSByLkOg{txO NFn1SFQzPDZ6MUKwOS=>
SK-N-SH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\E[4RwOC54MkWtNlAh|ryP M1W0XFQ5KGh? NYXkNmtiTE2VTx?= NFWyToNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHjLPZAzPDN7OUC3OC=>
SH-SY5Y NGK1W|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr4fFExNjZ{NT2yNEDPxE1? NYjDNoV6PDhiaB?= M4PYTWROW09? NWnYXodLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVKyOFM6QTB5NB?=
SK-N-SH MnTRRZBweHSxc3nzbUBCe3OjeR?= Mnr3OU8yOC9{MDFOwG0> NFLnUlc1QCCq MnK2SG1UVw>? MoDhbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MUCyOFM6QTB5NB?=
SH-SY5Y MnLwRZBweHSxc3nzbUBCe3OjeR?= NYnmVFk1PS9zMD:yNEDPxE1? NEPOS|I1QCCq MlLTSG1UVw>? NWDlcVEzcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MXuyOFM6QTB5NB?=
SK-N-SH Mnm3SpVv[3Srb36gRZN{[Xl? MYm1M|ExNzJyIN88US=> MWm0PEBp MV3EUXNQ NHfFPIFqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0 MXeyOFM6QTB5NB?=
SH-SY5Y M{PzVGZ2dmO2aX;uJGF{e2G7 NXL5NJkyPS9zMD:yNEDPxE1? MYm0PEBp Ml6xSG1UVw>? NUPsOG5TcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeC=> Ml7wNlQ{QTlyN{S=
SK-N-SH Ml;nSpVv[3Srb36gRZN{[Xl? NFLkOGcyNzVxMUCg{txO NXGw[VROPDhiaB?= NXryNXc4TE2VTx?= NGHqR5lqdmirYnn0d{BTTVRicHjvd5Bpd3K7bHH0bY9v M3jxO|I1Ozl7MEe0
SH-SY5Y NVTjRmE4TnWwY4Tpc44hSXO|YYm= NWTpblc{OS93L{GwJO69VQ>? M1HucFQ5KGh? MVPEUXNQ M1;FV4lvcGmkaYTzJHJGXCCyaH;zdIhwenmuYYTpc44> NYrrWJlqOjR|OUmwO|Q>
SK-N-SH NEHNdIlHfW6ldHnvckBCe3OjeR?= NWi1c29mPS9zMDFOwG0> MnTCOFghcA>? NVHQOWROTE2VTx?= M2PlWIlvcGmkaYTzJIh2dWGwIF7CJINmdGxibXnndoF1cW:w MnjNNlQ{QTlyN{S=
SH-SY5Y NIq4dGpHfW6ldHnvckBCe3OjeR?= MmjEOU8yOCEQvF2= MlrZOFghcA>? MWfEUXNQ NFnMb4pqdmirYnn0d{BpfW2jbjDORkBk\WyuIH3p[5JifGmxbh?= NGPmWFMzPDN7OUC3OC=>
SK-N-SH NWjXSJRKTnWwY4Tpc44hSXO|YYm= MWe1M|ExKM7:TR?= MWe0PEBp MnPjSG1UVw>? MYrpcohq[mm2czDoeY1idiCQQjDj[YxtKGmwdnHzbY9v MU[yOFM6QTB5NB?=
SH-SY5Y NVe1cIhRTnWwY4Tpc44hSXO|YYm= Mlq1OU8yOCEQvF2= MX:0PEBp MXrEUXNQ MoHTbY5pcWKrdIOgbJVu[W5iTlKgZ4VtdCCrbo\hd4lwdg>? M{S4Z|I1Ozl7MEe0
SK-N-SH M1PEVWZ2dmO2aX;uJGF{e2G7 MUW1JO69VQ>? MnjLNlQwPDhxN{KgbC=> MYPEUXNQ NHrvWm1{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEO[Q2K0JIFv\CCPTWCxOEBuWk6D NXjrdZJoOjR|OUmwO|Q>
SH-SY5Y M2H5eGZ2dmO2aX;uJGF{e2G7 M4TZWVUh|ryP MnjwNlQwPDhxN{KgbC=> MWTEUXNQ NHW2cld{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEO[Q2K0JIFv\CCPTWCxOEBuWk6D NIL1e5YzPDN7OUC3OC=>
SK-N-SH NIi1fo5HfW6ldHnvckBCe3OjeR?= M1[1XlUh|ryP M2KzTVQ5Nzd{IHi= NUDpdoNwTE2VTx?= MXTzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZidHjlJGNZS1J2IHHu[EBOVVBzNDDwdo91\Wmw M33yOVI1Ozl7MEe0
SH-SY5Y NYjMXHNVTnWwY4Tpc44hSXO|YYm= MYK1JO69VQ>? MlTMOFgwPzJiaB?= M4\oXWROW09? MnnQd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIITo[UBEYEOUNDDhcoQhVU2SMUSgdJJwfGWrbh?= NWjoWHhGOjR|OUmwO|Q>
HMEpC NYixbnY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;5N|Ehdk1vMUCwJO69VQ>? NWTwNWh5PDkEoHlCpC=> MVXEUXNQ Mm\KbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVHUfVdYOjRzM{i4OFM>
MCF-7 M16yRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7yTFAyKG6PLUGwNEDPxE1? MkT2OFjDqGkEoB?= MYPEUXNQ NH:4T3RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUWyOFE{QDh2Mx?=
ZR-75-1 M4fTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzWcpRpOSCwTT2xNFAh|ryP MVK0POKhcMLi NHvzem1FVVOR Ml7PbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NYPoW3lJOjRzM{i4OFM>
MDA-MB-231 NXrWOZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxJI5ONTFyMDFOwG0> NYXlTWJrPDkEoHlCpC=> NHXvUHZFVVOR MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWKyOFE{QDh2Mx?=
MDA-MB-468 M3nldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxJI5ONTFyMDFOwG0> NVvzXWN1PDkEoHlCpC=> M4TnTGROW09? M{PpUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MnTlNlQyOzh6NEO=
T-47-D NWTucoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxJI5ONTFyMDFOwG0> M3zSUFQ5yqCqwrC= NHS3SFdFVVOR NVu5[5hycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M37lelI1OTN6OESz
U251  MUnGeY5kfGmxbjDBd5NigQ>? NGC3SYIzNzRxOPMAje696oT|wrC= NUHvUJNSPi9zMj:yOEBp Mk\qSG1UVw>? M1f0ZYlv[3KnYYPld{B1cGViTFOzMWlKKGyndnXsJIlvKGFidHnt[U1l\XCnbnTlcpQh[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWSyN|c6QTh3Mh?=
U87MG NGrkZWdHfW6ldHnvckBCe3OjeR?= NEjRXVYzNzRxOPMAje696oT|wrC= MYC2M|EzNzJ2IHi= NIDT[lRFVVOR NVv3S3NNcW6lcnXhd4V{KHSqZTDMR|MuUUlibHX2[YwhcW5iYTD0bY1mNWSncHXu[IVvfCCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NF;4cYUzOzd7OUi1Ni=>
U251  M1\mZWZ2dmO2aX;uJGF{e2G7 NVfhfXpmPOLCid885qS{yqB? MWeyM|YwOTJiaB?= MWTEUXNQ Mlyyd5VxeHKnc4Pld{Bj[XOjbDDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1cW:wIH;mJHM3KCiVMkO1M|I{PiluIETFMWJROSBqVEO3M|Q3MSxiYX7kJGFsfCBqU{S3N{khcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NHPZV3YzOzd7OUi1Ni=>
U87MG NIW1WGpHfW6ldHnvckBCe3OjeR?= M4fDblTjiIoQvPMEt:Kh NW\wOG43Oi94L{GyJIg> NGPTS4dFVVOR NFfrTpd{fXCycnXzd4V{KGKjc3HsJIxmfmWuczDv[kBxcG:|cHjvdplt[XSrb36gc4YhWzZiKGOyN|UwOjN4KTygOGUuSlBzIDjUN|cwPDZrLDDhcoQhSWu2IDjTOFc{MSCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi MWqyN|c6QTh3Mh?=
H1650  MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXF[HBKSzVyPUOuOeKyOS5{IN88US=> M3nBNFI{Ojd2N{W4
HUVECs  MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWW3NkBp NEixclVKSzVywrC9JFcvOSEQvH3vcE9N NX\FclQ6OjJ4MUGwNlc>
KYN-2  M3Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHBPZY4OiCq NFH2dIxKSzVywrC9JFgvOSEQvH3vcE9N M2XrVFIzPjFzMEK3
HuH-7  NWTlTII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fORlczKGh? M4jRPWlEPTEEoE2gPU41KM7:bX;sM2w> NUG3eHVFOjJ4MUGwNlc>
HUVECs  NYizfYx6TnWwY4Tpc44hSXO|YYm= M2[xPVEwPS9zMDFOwG0> Mn:5NUBp MXnzbYdvcW[rY3HueIx6KGmwaHnibZR{KF[HR1\SMVIheGixc4Doc5J6dGG2aX;u M{nLWFIzPjFzMEK3
HAK1-B NF;4OnNHfW6ldHnvckBCe3OjeR?= NYX5SHZYOS93L{GwJO69VQ>? MmTYNUBp Ml3Ed5VxeHKnc4Pld{BGT0[UIIDoc5NxcG:{eXzheIlwdg>? MX6yNlYyOTB{Nx?=
UM-22A NXjLVZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfFNE03KM7:TR?= NXj5VopjPzJiaB?= NVzFeGhKTE2VTx?= MnnobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MViyNlMxPzd|NR?=
UM-22B MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;zNE03KM7:TR?= NHTQfW04OiCq M{TqW2ROW09? NWHqSVVzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NID0RXQzOjNyN{ezOS=>
PCI-37A NEnHNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2yNWxuOC14IN88US=> M1myd|czKGh? NFy1enBFVVOR NIL1Tm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGPTblQzOjNyN{ezOS=>
PCI-37B NGPBUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKwMVYh|ryP M4nyclczKGh? NH;Oc21FVVOR Mlq3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1;od|IzOzB5N{O1
PCI-15B M{LJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMVYh|ryP M3vqelczKGh? NYDHV202TE2VTx?= NWnkRZVYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVOyNlMxPzd|NR?=
SCC-25 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfu[|NROC14IN88US=> M3O1VlczKGh? Mk\aSG1UVw>? MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXvFSYQyOjJ|MEe3N|U>
UM-22A MUfGeY5kfGmxbjDBd5NigQ>? MnHtNE0yOCEQvF2= MUmyOEBp NYnNUldTTE2VTx?= MmDpbY5pcWKrdIOgeIhmKGGldHn2ZZRqd25ib3[geIhmKEWJRmKgeJlzd3OrbnWgb4lv[XOnIHHu[EBidHOxIHTlZ5Jm[XOnczD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCob4Ltd{Bw\iC2aHWg[I94dnO2cnXhcUB{cWewYXzpcoch\WynbXXueJMtKFOWQWSzJIFv\CCPQWDL MVGyNlMxPzd|NR?=
UM-22B MkS3SpVv[3Srb36gRZN{[Xl? NIjuXXUxNTFyIN88US=> NXvCXZY3OjRiaB?= NVHI[49KTE2VTx?= NVO3To1wcW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YhfGinIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFv\CCjbIPvJIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDmc5JueyCxZjD0bIUh\G:5boP0doVidSC|aXfuZYxqdmdiZXzlcYVvfHNuIGPURXQ{KGGwZDDNRXBM MU[yNlMxPzd|NR?=
PCI-15B Ml\lSpVv[3Srb36gRZN{[Xl? NW\lR5dVOC1zMDFOwG0> NWTQToFiOjRiaB?= Ml3iSG1UVw>? MYTpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjD0bIUhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYX7kJIFte29iZHXjdoVie2W|IITo[UBmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKG[xcn3zJI9nKHSqZTDkc5dve3S{ZXHtJJNq\26jbHnu[{BmdGWvZX70d{whW1SDVEOgZY5lKE2DUFu= MmPXNlI{ODd5M{W=
PCI-37A MkXoSpVv[3Srb36gRZN{[Xl? Mkm4NUDPxE1? NHLkO4QzPCCq M3u0TmROW09? NYG2ZY93\G:5boLl[5Vt[XSnczDWSWdHKHC{b3T1Z5Rqd25? MnLyNlI{ODd5M{W=
UM-22A MoPtSpVv[3Srb36gRZN{[Xl? M4C3NFEh|ryP M1jVfFI1KGh? NFSwdGdFVVOR MUPkc5dvemWpdXzheIV{KF[HR1[gdJJw\HWldHnvci=> Ml\nNlI{ODd5M{W=
PCI-15B MnHDSpVv[3Srb36gRZN{[Xl? NYDYTmtsOSEQvF2= MlriNlQhcA>? MX\EUXNQ NUjnfZRp\G:5boLl[5Vt[XSnczDWSWdHKHC{b3T1Z5Rqd25? NXfkfYZ[OjJ|MEe3N|U>
PCI-15B NV3RelR{UW64YYPpc44hSXO|YYm= NH3mcYczPCCq NFyyfFhFVVOR M2LFcWVEPTB;NUW4JI5O NWrxNXhXOjJ|MEe3N|U>
PCI-37A NWjsOmMyUW64YYPpc44hSXO|YYm= MlrZNlQhcA>? MY\EUXNQ MnPaSWM2OD1zNkm1JI5O NH3CXZczOjNyN{ezOS=>
UM-22A MlXUTY53[XOrb36gRZN{[Xl? NIDXVIwzPCCq NFfYSJVFVVOR M3q4e2VEPTB;MD6zJI5O M3;EPFIzOzB5N{O1
SCC-25 MXrJcpZie2mxbjDBd5NigQ>? NX2zOWJqOjRiaB?= M2HLfmROW09? NF;DNm5GSzVyPUGwJI5O MUKyNlMxPzd|NR?=
UM-22B NYPBS5F3UW64YYPpc44hSXO|YYm= NVu5WXc5OjRiaB?= MnXpSG1UVw>? MUnFR|UxRTJ2MkSgcm0> NHTkb3kzOjNyN{ezOS=>
PCI-37B MoPFTY53[XOrb36gRZN{[Xl? NILzW5ozPCCq NWPhbZZCTE2VTx?= M2jCRWVEPTB;MUeyOkBvVQ>? NXrL[5JvOjJ|MEe3N|U>
201T NW\oW3I2TnWwY4Tpc44hSXO|YYm= MVGyMlUh|ryP MXK0PEBp M4fwOmROW09? M124Z4lvcGmkaYTzJJBpd3OyaH:tUWFRUyCob3zsc5dqdmdiRVfG Mo\PNlIzPTh2N{[=
273T  MnrWSpVv[3Srb36gRZN{[Xl? MVSyMlUh|ryP MVy0PEBp NHnoNnFFVVOR NHjldJVqdmirYnn0d{BxcG:|cHjvMW1CWEtiZn;scI94cW6pIFXHSi=> NEHrR4QzOjJ3OES3Oi=>
A549 MoC5SpVv[3Srb36gRZN{[Xl? NE\YbZMzNjVizszN MX20PEBp NIPuOY5FVVOR MkDBbY5pcWKrdIOgdIhwe3Cqbz3NRXBMKG[xbHzve4lv\yCHR1[= NUDWTXl{OjJ{NUi0O|Y>
201T  MW\GeY5kfGmxbjDBd5NigQ>? M{X4cFEwPS9zMDFOwG0> NH\xS441QCCq MlnWSG1UVw>? M4\abIJtd2OtczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDpcoR2[2WmIHL5JHZGT0[F MmjHNlIzPTh2N{[=
H2052 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ONnlnUUN3ME2xMlA4yrFyLkC0JO69VQ>? Mmj6NlE6PzB6N{S=
H2452 NFPUUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzxTWM2OD1|LkWyxtEyNjF|IN88US=> NWDIVmg5OjF7N{C4O|Q>
H28 NITQVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPTWM2OD1yLkOyxtExNjB5IN88US=> MXSyNVk4ODh5NB?=
MSTO-211H MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNENCtVAvODNizszN NY\rWGd3OjF7N{C4O|Q>
Hth83 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDNOZA4OiCq M1LPWmROW09? M1[5Z2lEPTB;Mz6zNEDDuSByLk[2JO69VQ>? M1XIcFIyOjJyNEe3
C643 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTsO|IhcA>? MWjEUXNQ MWTJR|UxRTNwNkWgxtEhOS5{MjFOwG0> NXjCN4JjOjF{MkC0O|c>
8505C NYrGXmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLnOoM4OiCq Ml\BSG1UVw>? NVHiU4RPUUN3ME23MlU3KMLzIEGuNVMh|ryP Mo\BNlEzOjB2N{e=
Hth74 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu3NkBp M1zXcWROW09? MoC2TWM2OD16LkW2JOKyKDFwMEGg{txO MXKyNVIzODR5Nx?=
SW1736 M3PFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzRNlQ4OiCq M3v2PWROW09? MX;JR|UxRTlwMEWgxtEhOC53NTFOwG0> MnTPNlEzOjB2N{e=
Hth7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvMN5Q4OiCq M4rEU2ROW09? MVTJR|UxRTlwNk[gxtEhOC5|ODFOwG0> NH3zTnEzOTJ{MES3Oy=>
Hth104 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfxO|IhcA>? Mlm4SG1UVw>? NXm4Z2JVUUN3ME5CtVE3Njl6INMxJG5CKM7:TR?= M4DUU|IyOjJyNEe3
HTB3 M3;TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnkepJUOC1{MDFOwG0> NXLhOlRIOjUEoHi= NH2xRZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoXZNVkzOjB{NU[=
HT1376 NUHiOXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKwMVIxKM7:TR?= M2\iV|I1yqCq NUfyO4tQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MmLSNVkzOjB{NU[=
RT4 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID0dYgxNTJyIN88US=> Mn61NlTDqGh? Mnv0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3nWSlE6OjJyMkW2
J82 M{DYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTWcGFDOC1{MDFOwG0> M3G3d|I1yqCq M4\1XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWexPVIzODJ3Nh?=
CRL1749 NVrhdXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLvdG4xNTJyIN88US=> NEfuVZkzPMLiaB?= NHe2PItqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MmDGNVkzOjB{NU[=
T24 NVXve3IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3HNE0zOCEQvF2= MYmyOOKhcA>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MX2xPVIzODJ3Nh?=
SUP M2HpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\uR|AuOjBizszN MYCyOOKhcA>? MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlL1NVkzOjB{NU[=
HTB9 NX;2[GVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fKUlAuOjBizszN M2jwZVI1yqCq MlTLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlzENVkzOjB{NU[=
ACC3 NVvaWHFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPBNE0yOCEQvF2= MX63NkBp MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NEHBNVgyQDZ7OECyOS=>
ACC2 Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\wNE0yOCEQvF2= M4Toc|czKGh? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MVGxPFY6QDB{NR?=
ACCM M4nRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXPNE0yOCEQvF2= NFPPVXc4OiCq NFfR[YRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFf1ZmQyQDZ7OECyOS=>
ACC3 MoDsRZBweHSxc3nzbUBCe3OjeR?= NXLpT4tIOC1zMDFOwG0> NHL1bFg4OiCq MlWxbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M13XclE5Pjl6MEK1
ACC2 NFHzfHRCeG:ydH;zbZNqKEG|c3H5 MXywMVExKM7:TR?= NH:w[lI4OiCq NU\Rd3NIcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MmPYNVg3QThyMkW=
ACCM Mo[zRZBweHSxc3nzbUBCe3OjeR?= Mne1NE0yOCEQvF2= NEDwPGk4OiCq MXjpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NXXRTFdHOTh4OUiwNlU>
EHMES-1 NV\wbWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3lcINNPzJiaB?= NVL4[2VkTE2VTx?= M2HPSGlEPTB;MUCuOkDPxE1? NYHyZlA2OTh|NkSyOFg>
EHMES-10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV62cFBlPzJiaB?= MX;EUXNQ Mm\LTWM2OD1yLkOg{txO MofRNVg{PjR{NEi=
211H NUPXZVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp NXfZVnJlTE2VTx?= M4\PeGlEPTB;Mj6yJO69VQ>? MljCNVg{PjR{NEi=
H28 NXnkVnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3LZXQ4OiCq M17MfGROW09? NX3QU2FPUUN3ME2xMlgh|ryP MVqxPFM3PDJ2OB?=
H2052 NF3FcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NkBp MljoSG1UVw>? M3ftT2lEPTB;OD6wJO69VQ>? MnHvNVg{PjR{NEi=
H2452 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\5UFczKGh? Mo\oSG1UVw>? NUTpdmdMUUN3ME21MlUh|ryP NE\XfmsyQDN4NEK0PC=>
CNE-1 NV7yUIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf1OmFiOC5zLUK1MlYh|ryP NV:1RnMxPDhiaB?= NE\H[ItKSzVyPUOuOkDPxE1? NFi4WFMyPzZ|MU[0Oi=>
CNE-2 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHiXYcxOC5zLUK1MlYh|ryP MXO0PEBp NUnqbHJKUUN3ME22MlIh|ryP MnnaNVc3OzF4NE[=
C666-1 M1LiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPHZmVTOC5zLUK1MlYh|ryP M2SyVlQ5KGh? MVfJR|UxRTJ|LkSg{txO MnTPNVc3OzF4NE[=
CNE-1 M4XVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuwMlEuOjVwNjFOwG0> M{TNUVczKGh? M{HvbWlEPTB;Mj6zJO69VQ>? NUW2RVQzOTd4M{G2OFY>
CNE-2 M4jGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlEuOjVwNjFOwG0> MYK3NkBp MYnJR|UxRTNwNjFOwG0> MnLvNVc3OzF4NE[=
C666-1 NI\aUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqwMlEuOjVwNjFOwG0> M1rXfFczKGh? M3fOOmlEPTB;ND64OkDPxE1? MXOxO|Y{OTZ2Nh?=
CNE-1 M4Ppd2Z2dmO2aX;uJGF{e2G7 M{fwVVYh|ryP NILNZogzPCCq NFezOVVl\WyjeYOgS|AwTzFiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> MUixO|Y{OTZ2Nh?=
CNE-2 M{LiZ2Z2dmO2aX;uJGF{e2G7 NGjxV|Q3KM7:TR?= NU\qPY9WOjRiaB?= NV3O[XE5\GWuYYnzJGcxN0dzIHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44> NH;YPFEyPzZ|MU[0Oi=>
C666-1 NFnhdYhHfW6ldHnvckBCe3OjeR?= MlrKOkDPxE1? MmC4NlQhcA>? NH7RUGtl\WyjeYOgS|AwTzFiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> NUDN[|FOOTd4M{G2OFY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK / p-AKT / AKT ; 

PubMed: 19622715     


Logarithmically growing U87 and T98G cells were incubated with varying concentrations of vandetanib for 24 h. The cells were lysed, and equal amounts of proteins were separated by SDS-PAGE and probed with specific antibodies against phospho-ERK, and phospho-Akt. Western blot analysis was performed as described under Materials and Methods. The blots were subsequently stripped and reprobed against total ERK, Akt, or β-actin. 

p-EGFR / EGFR ; 

PubMed: 20629091     


Dose-dependent inhibition of EGFR phosphorylation by vandetanib in the human HNSCC cell lines FaDu, and SCC61. Cells were serum-starved, treated for 90 min with vandetanib at the indicated concentrations, and then stimulated for 15 min with 50 ng/ml EGF. Whole-cell lysates were obtained and subjected to Western immunoblotting to resolve proteins. Antibodies to total (unphosphorylated) receptors and β-actin were used as protein loading controls.

19622715 20629091
Growth inhibition assay
Cell viability; 

PubMed: 24261856     


(A) MTT assays of HUVEC with α-santalol, vandetanib or sunitinib, respectively. (B) MTT assays of PC-3 cells with α-santalol, vandetanib or sunitinib, respectively.

24261856
In vivo Vandetanib (2.5 mg/kg, i.v.), reverses a VEGF-induced hypotension by 63% but does not significantly affect a bFGF-induced hypotension. Vandetanib (100 mg/kg) inhibits the tumor-induced blood vessel formation by 79%. Vandetanib (12.5-100 mg/kg, orally) shows great tumor growth inhibition in human tumor xenografts including Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung, with little effects on body weight. [1] In PC3wt xenografts, administration of Vandetanib alone exerts paradoxical tumor growth stimulating effects. In PC3R xenografts, the low dose of Vandetanib (25 mg/kg) has no significant effect relative to control, whereas the high dose (50 mg/kg) significantly inhibits tumor growth compared with control. In contrast, the high-dose combination reveals a significant negative interaction between Vandetanib 50 mg/kg and docetaxel 30 mg/kg in PC3R cells. [3] In tumor-bearing mice, Vandetanib suppresses phosphorylation of VEGFR2 and EGFR in tumor tissues, significantly decreases tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and up-regulates VEGF, TGF-alpha and EGF in tumor tissues. Treatment with Vandetanib is not associated with serious adverse events, including ALT abnormality, bone marrow suppression or body weight loss. [4] Vandetanib treatment of nude mice bearing palpable GEO colon cancer xenografts (which are sensitive to inhibition of EGFR signaling) induces dose-dependent tumor growth inhibition. [5]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase inhibition:

Vandetanib is incubated with enzyme, 10 mM MnCl2, and 2 μM ATP in 96-well plates coated with a poly(Glu, Ala, Tyr) 6:3:1 random copolymer substrate. Phosphorylated tyrosine is then detected by sequential incubation with a mouse IgG anti-phosphotyrosine 4G10 antibody, a horseradish peroxidase-linked sheep antimouse immunoglobulin antibody, and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid). This methodology is adapted to examine selectivity versus tyrosine kinases associated with EGFR, PDGFRβ, Tie-2, FGFR1, c-kit, erbB2, IGF-1R, and FAK. All enzyme assays (tyrosine or serine-threonine) used appropriate ATP concentrations at or just below the respective Km (0.2–14 μM). Selectivity versus serine-threonine kinases (CDK2, AKT, and PDK1) is examined using a relevant scintillation proximity-assay (SPA) in 96-well plates. CDK2 assays contained 10 mM MnCl2, 4.5 μM ATP, 0.15 μCi of [γ-33 P]ATP/reaction, 50 mM HEPES (pH 7.5), 1 mM DTT, 0.1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 10 mM sodium glycerophosphate, 1 mg/mL BSA fraction V, and a retinoblastoma substrate (part of the retinoblastoma gene, 792–928, expressed in a glutathione S-transferase expression system; 0.22 μM final concentration). Reactions are allowed to proceed at room temperature for 60 minutes before quenching for 2 hours with 150 μL of a solution containing EDTA (62 mM final concentration), 3 μg of a rabbit immunoglobulin anti-glutathione S-transferase antibody and protein A SPA-polyvinyltoluene beads (0.8 mg/reaction). Plates are then sealed, centrifuged (1200× g for 5 minutes), and counted on a Microplate scintillation counter for 30 seconds.
Cell Research:

[1]

- Collapse
  • Cell lines: Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung cells
  • Concentrations: 0.1–100 μM
  • Incubation Time: 72 hours
  • Method:

    Tumor cells are plated in their respective media at predetermined densities that are known to enable logarithmic cell growth during the period of assay (PC-3, 500 cells/well; all others, 1000 cells/well). Plates are incubated for 24 hours (37 °C with CO2) before the addition of Vandetanib (0.1–100 μM) or vehicle (0.1% DMSO in medium). Plates are reincubated for an additional 72 hours before assessing cell proliferation by [3 H]thymidine incorporation by a beta counter.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Female athymic (nu/nu genotype) Swiss mice with PC-3, Calu-6, SKOV-3, and MDA-MB-231 tumors
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 50 mg/kg/day, or 100 mg/kg/day
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.41 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.35
Formula

C22H24BrFN4O2

CAS No. 443913-73-3
Storage powder
in solvent
Synonyms N/A
Smiles CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03291379 Completed Drug: BTG-002814 (vandetanib-eluting radiopaque beads) Carcinoma Hepatocellular|Metastatic Colorectal Cancer Biocompatibles UK Ltd May 17 2017 Early Phase 1
NCT02495103 Completed Drug: Vandetanib|Drug: Metformin|Drug: Vandetanib/Metformin Renal Cell Carcinoma|Hereditary Leiomyomatosis|Renal Cell Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 26 2015 Phase 1|Phase 2
NCT02530411 Unknown status Drug: Fulvestrant|Drug: Vandetanib Neoplasms Velindre NHS Trust|Cancer Research UK|AstraZeneca April 2015 Phase 2
NCT02268734 Unknown status -- Metastatic Sporadic Medullary Thyroid Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano April 2014 --
NCT01876784 Active not recruiting Drug: Vandetanib (SAR390530)|Drug: Placebo Differentiated Thyroid Cancer Genzyme a Sanofi Company|Sanofi September 17 2013 Phase 3
NCT01661179 Completed Drug: Vandetanib 300mg Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Genzyme a Sanofi Company|Sanofi November 2012 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Vandetanib (ZD6474) | Vandetanib (ZD6474) supplier | purchase Vandetanib (ZD6474) | Vandetanib (ZD6474) cost | Vandetanib (ZD6474) manufacturer | order Vandetanib (ZD6474) | Vandetanib (ZD6474) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID